open access

Vol 6, No 5 (2010)
Review paper
Published online: 2011-01-19
Get Citation

The role of pathologist in cancer patients selection for EGFR-targeted therapy

Wojciech P. Olszewski, Włodzimierz T. Olszewski
Onkol. Prak. Klin 2010;6(5):228-235.

open access

Vol 6, No 5 (2010)
REVIEW ARTICLES
Published online: 2011-01-19

Abstract

Targeted therapy has become an important modality of cancer treatment in the last decade. Drugs against EGFR and HER2 e.g. erlotinib, cetuximab or trastuzumab proved its role n therapy. They are managed as registered and recommended modalities of lung, alimentary tract and breast carcinoma. Significance of targeted treatment is a common effect of drug action and patient selection. Only a part of patients with tumors belonging to a specific histological type of cancer can benefit from targeted therapy. Determining predictive factor — informating on potential response to therapy — is essential for proper treatment in targeted therapy. Patients’ selection is accomplished by pathological methods with help of molecular biology techniques. Patient selection for targeted treatment and predictive factors evaluation criteria as well as establishing connections with traditional tumor characteristics (e.g. histological type, grade, stage) are continuously under research. Predictive factors are also investigated for traditional chemotherapeutics in recent years. Value of particular predictive factor depends on choice of evaluation method.

Onkol. Prak. Klin. 2010; 6, 5: 228–235

Abstract

Targeted therapy has become an important modality of cancer treatment in the last decade. Drugs against EGFR and HER2 e.g. erlotinib, cetuximab or trastuzumab proved its role n therapy. They are managed as registered and recommended modalities of lung, alimentary tract and breast carcinoma. Significance of targeted treatment is a common effect of drug action and patient selection. Only a part of patients with tumors belonging to a specific histological type of cancer can benefit from targeted therapy. Determining predictive factor — informating on potential response to therapy — is essential for proper treatment in targeted therapy. Patients’ selection is accomplished by pathological methods with help of molecular biology techniques. Patient selection for targeted treatment and predictive factors evaluation criteria as well as establishing connections with traditional tumor characteristics (e.g. histological type, grade, stage) are continuously under research. Predictive factors are also investigated for traditional chemotherapeutics in recent years. Value of particular predictive factor depends on choice of evaluation method.

Onkol. Prak. Klin. 2010; 6, 5: 228–235

Get Citation

Keywords

predictive factors; targeted therapy; pathology; molecular biology

About this article
Title

The role of pathologist in cancer patients selection for EGFR-targeted therapy

Journal

Oncology in Clinical Practice

Issue

Vol 6, No 5 (2010)

Article type

Review paper

Pages

228-235

Published online

2011-01-19

Bibliographic record

Onkol. Prak. Klin 2010;6(5):228-235.

Keywords

predictive factors
targeted therapy
pathology
molecular biology

Authors

Wojciech P. Olszewski
Włodzimierz T. Olszewski

References (8)
  1. Langfort R. Rozpoznanie mikroskopowe raka płuca na podstawie drobnego materiału biooptycznego. Pol J Pathol. 2010; 61(supl. 1).
  2. Olszewski WT. Diagnostyka cytologiczna raka płuca. . Pol. J. Pathol. 2010; supl. 1.
  3. Szumera-Ciećkiewicz A, Olszewski WT. Miejsce patomorfologii w terapii celowanej raka płuca. Pol J Pathol. 2010; 61(supl. 1).
  4. Olszewski WP. Molekularne wskaźniki rokownicze i predykcyjne. In: Jassem J, Krzakowski M. ed. Rak piersi — praktyczny przewodnik dla lekarzy. Via Medica, Gdańsk 2009: 80–96.
  5. Olszewski WP. Patomorfologiczna selekcja chorych do terapii systemowej. Pol J Pathol. 2009; 3(supl. 1): 28–33.
  6. Hamilton SR. Targeted therapy of cancer: new roles for pathologists in colorectal cancer. Mod Pathol. 2008; 21 Suppl 2: S23–S30.
  7. Rüschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010; 457(3): 2299–2307.
  8. Van Cu, Kang Y, Chung H, et al. Efficacy result from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in the first-line human epidermal growth factor receptor 2 (HER2) positive advanced gastric cancer (GC). J Clin Oncol. 2009; 27: 18S.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl